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Abstract
Objective
To characterize, among European and Han Chinese populations, the genetic predictors of
maculopapular exanthema (MPE), a cutaneous adverse drug reaction common to antiepileptic
drugs.
Methods
We conducted a case-control genome-wide association study of autosomal genotypes, in-
cluding Class I and II human leukocyte antigen (HLA) alleles, in 323 cases and 1,321 drug-
tolerant controls from epilepsy cohorts of northern European and Han Chinese descent.
Results from each cohort were meta-analyzed.
Results
We report an association between a rare variant in the complement factor H–related 4
(CFHR4) gene and phenytoin-induced MPE in Europeans (p = 4.5 × 10–11; odds ratio [95%
conﬁdence interval] 7 [3.2–16]). This variant is in complete linkage disequilibrium with
a missense variant (N1050Y) in the complement factor H (CFH) gene. In addition, our results
reinforce the association between HLA-A*31:01 and carbamazepine hypersensitivity. We did
not identify signiﬁcant genetic associations with MPE among Han Chinese patients.
Conclusions
The identiﬁcation of genetic predictors of MPE in CFHR4 and CFH, members of the
complement factor H–related protein family, suggest a new link between regulation of the
complement system alternative pathway and phenytoin-induced hypersensitivity in European-
ancestral patients.
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Idiosyncratic cutaneous adverse drug reactions (cADRs) can
have a genetic predisposition. The HLA-B*15:02 allele is
a predictor of carbamazepine-induced Stevens-Johnson syn-
drome and toxic epidermal necrolysis (SJS/TEN) in indi-
viduals of Han Chinese and Southeast Asian descent, while
a recent meta-analysis suggests that the allele is also a signiﬁ-
cant risk factor for oxcarbazepine-, phenytoin-, and
lamotrigine-induced SJS/TEN.1,2 However, the association
with HLA-B*15:02 does not extend to the milder but more
common maculopapular exanthema (MPE) phenotype, and
the allele is speciﬁc to individuals of Asian descent, limiting
clinical utility across populations.3,4 HLA-A*31:01 has been
conﬁrmed as a transethnic risk factor for carbamazepine-
induced cADRs, with the allele observed across populations of
European, Japanese, and Korean descent.5–8 Recently, HLA-
A*24:02 has been shown to associate with SJS in Han Chinese
patients, irrespective of causal drug studied.9 Genetic variation
beyond the major histocompatibility locus has also been as-
sociated with cADRs. The CYP2C9*3 allele correlates with
phenytoin hypersensitivity in Han Chinese from Taiwan,10
with a similar eﬀect reported in a Thai population.11 However,
a genome-wide association study (GWAS) of lamotrigine and
phenytoin-induced cADRs in Europeans did not detect sig-
niﬁcant predictors.12 A summary of the associated genetic risk
variants for cADRs in various populations is provided in table
e-1 (links.lww.com/WNL/A56).
The EpiPGX Consortium was established to identify genetic
markers of epilepsy treatment response. The International
League Against Epilepsy Complex Genetics Consortium
(ILAE-CGC) facilitates the discovery of genetic variants
inﬂuencing epilepsy predisposition.13 The EPIGEN consor-
tium is a worldwide epilepsy genetics research framework and
the Canadian Pharmacogenomics Network for Drug Safety
(CPNDS) is an active surveillance network focused on
identifying genomic markers of severe adverse drug reactions
(ADRs) in children and adults.14 Collaboration among these
consortia has provided detailed phenotypes and genotypes for
over 15,000 epilepsy cases, for the investigation of antiepi-
leptic drug (AED)–induced MPE.
Availing of the joint resources of EpiPGX, ILAE-CGC,
EPIGEN, and CPNDS, this study aimed to characterize,
among European and Han Chinese populations, the genetic
predictors of MPE, a cutaneous ADR common to particular
AEDs. Speciﬁcally, we set out to test the following hypothe-
ses: (1) whether population-speciﬁc genetic variants predict
MPE; (2) whether transethnic genetic variants predict MPE;
(3) whether population-speciﬁc genetic variants predict AED-
speciﬁc MPE; and (4) whether transethnic genetic variants
predict AED-speciﬁc MPE.
Methods
Standard protocol approvals, registrations,
and patient consents
All study participants provided written, informed consent for
genetic analysis. Local institutional review boards approved
study protocols at each contributing site.
Study design
We conducted a retrospective case-control study in individuals
of European and Han Chinese ethnicity. Participants were ex-
posed to carbamazepine, lamotrigine, phenytoin, or oxcarba-
zepine. Our analyses were structured to test genetic variants for
association with MPE within and across both of the broad
ancestral groups, through logistic regression of genotype dosage
and subsequent meta-analysis of regression coeﬃcients. We
tested for association with (1) aromatic AED-induced MPE vs
controls tolerant to at least 3 aromatic AEDs, (2)
carbamazepine-induced MPE vs carbamazepine-tolerant con-
trols, (3) lamotrigine-induced MPE vs lamotrigine-tolerant
controls, and (4) phenytoin-induced MPE vs phenytoin-
tolerant controls. Due to small sample size, oxcarbazepine-
related MPE was not analyzed as an individual case cohort.
Cohorts and phenotype definition
Epilepsy cohorts from the ILAE-CGC, EpiPGX, and EPIGEN
Consortia were included in the discovery GWAS meta-
analysis (table 1). A European-descent replication cohort was
assembled from sites in Brazil, Canada (via CPNDS), Liver-
pool, and other sites across the United Kingdom. Cases were
deﬁned as having MPE attributed to carbamazepine, lamo-
trigine, phenytoin, or oxcarbazepine as determined by their
clinician, occurring within 3months of initiation and resolving
upon dose reduction or AED withdrawal. Control patients
trialed carbamazepine, lamotrigine, phenytoin, or oxcarbaze-
pine for at least 3months without reporting a cADR. Epilepsy-
speciﬁc patient demographics are presented in table e-2 (links.
lww.com/WNL/A56).
Genotyping and imputation
Genotyping of a subset of EpiPGX samples was performed at
deCODE Genetics (Reykjavik, Iceland) using Illumina (San
Glossary
ADR = adverse drug reaction; AED = antiepileptic drug; cADR = cutaneous adverse drug reaction; CFH = complement factor
H;CFHR4 = complement factor H–related 4 gene;CI = conﬁdence interval;CPNDS =Canadian Pharmacogenomics Network
for Drug Safety;GWAS = genome-wide association study;HLA = human leukocyte antigen; ILAE-CGC = International League
Against Epilepsy Complex Genetics Consortium; MPE = maculopapular exanthema; OR = odds ratio; SJS/TEN = Stevens-
Johnson syndrome and toxic epidermal necrolysis; SNP = single nucleotide polymorphism.
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Diego, CA) OmniExpress-12 v1.1 and OmniExpress-24 v1.1
single nucleotide polymorphism (SNP) arrays. The re-
mainder of samples were genotyped locally using various
Illumina beadchip SNP arrays, details of which are published
elsewhere.13 Genotyping and imputation quality control is
described in appendix e-1 (links.lww.com/WNL/A57).
Study power
We estimated that the study had 80% power to detect a ge-
netic predictor of relative risk (approximated to odds ratio)
≥3 with an allele frequency ≥2% and an α level of 1.25 × 10−8.
Power for AED-speciﬁc and population-speciﬁc analyses are
detailed in appendix e-1 (links.lww.com/WNL/A57).
Statistical analyses
Association analyses were conducted within the European
and Asian subgroups using an additive logistic regression
model. To account for genotype uncertainty, SNPTEST was
used to apply a missing data likelihood score model that
included sex, clinical site, and 5 principal components as
covariates to control for bias and population stratiﬁcation.15
Fixed eﬀects meta-analyses were conducted across the Eu-
ropean and Asian subgroups using the software package
METAL, applying genomic control correction within
cohorts.16 The threshold for statistical signiﬁcance was set at
1.25 × 10−8, reﬂecting an empirical Bonferroni correction for
4 tests, of the standard 5 × 10−8 genome-wide signiﬁcance
threshold. Conditional association analysis was performed
on loci containing signiﬁcant markers to establish whether
other genetic variants in the region (1 Mb upstream and
downstream) were independently associated with MPE. The
conditional threshold for signiﬁcance was set at 5 × 10−6,
based on a genome-wide estimation of 10,000 imputed var-
iants per 2 MB region.13 We applied the Stouﬀer z trend test
to the combined results from the discovery and replication
cohorts.
Confirmatory genotyping
Where an association signal satisﬁed the threshold for sig-
niﬁcance, additional genotyping and resequencing were per-
formed in a subset of patients and results were compared with
imputation dosage ﬁles. The variant rs78239784 was
conﬁrmed by Sanger sequencing in 100 patients from the
original discovery cohort. For the purpose of replication, we
genotyped the rs78239784 variant in an independent cohort
of 13 phenytoin-induced MPE cases and 88 phenytoin-
tolerant controls.
Results
Cohort description
In total, 375 MPE cases and 1,321 controls satisﬁed our cri-
teria for inclusion in the discovery analyses (see Methods and
table 1). There were 16 patients with cross-reactivity to 2 or
more aromatic AEDs, 8 of whom were hypersensitive to
carbamazepine and lamotrigine. Genome-wide array data for
323 cases and 1,321 controls were available for analysis. Broad
European or Han Chinese ancestry was assigned to each
participant according to principal components analysis (ﬁgure
e-1, links.lww.com/WNL/A55).
Genome-wide association analysis of broad
aromatic AED–induced MPE
After quality control (see appendix e-1, ﬁgure e-2, links.lww.
com/WNL/A55, for details), 3,693,290 variants remained for
analysis in the European dataset and 4,402,554 variants in the
Han Chinese dataset. We only considered autosomal SNPs in
our analyses. To test hypothesis (1), that population-speciﬁc
genetic markers predispose to MPE, a logistic regression
analysis of all MPE cases was performed separately in the
European and Han Chinese ancestral subgroups. We did not
observe any genome-wide signiﬁcant markers for MPE due to
any aromatic AED in either Europeans or Han Chinese. The
study was powered to detect an eﬀect of relative risk >3.5 in
the European cohort and >5 in the Han Chinese.
To test hypothesis (2), that transethnic genetic markers
predispose to MPE, a ﬁxed-eﬀects meta-analysis of the asso-
ciation results for European and Han Chinese ancestral sub-
groups was performed. We did not observe any genome-wide
signiﬁcant markers for MPE shared among European or Han
Chinese subgroups (ﬁgure 1A). This analysis was powered to
detect an eﬀect size >3.
Table 1 Breakdown of antiepileptic drug (AED)–induced maculopapular exanthema (MPE) cases and AED-tolerant
controls in discovery dataset
Ethnicity
All aromatic AEDs CBZ LTG PHT
MPEa Controlb MPE Control MPE Control MPE Control
European 259 979 95 869 118 812 52 472
Han Chinesec 116 342 85 197 16 32 22 58
Subtotal 375 1,321 180 1,066 134 844 74 530
Abbreviations: CBZ = carbamazepine; ILAE = International League Against Epilepsy; LTG = lamotrigine; PHT = phenytoin.
a Individual participant counts only, despite 16 patients being cross-reactive to more than 1 AED.
b A total of 1,321 controls were tolerant to all 3 of CBZ, LTG, and PHT.
c Fifty-two carbamazepine-induced MPE cases from Guangzhou were available for analysis of human leukocyte antigen serotype data only.
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Genome-wide association analysis of specific
aromatic AED–induced MPE
To test hypothesis (3), that genetic variants for MPE are
AED-speciﬁc and population-speciﬁc, logistic regression
analyses of AED-speciﬁc MPE was performed separately in
the European and Han Chinese ancestral groups (ﬁgures e-3
and e-4, links.lww.com/WNL/A55). Within the European
subgroup, HLA-A*31:01 was signiﬁcantly associated with
carbamazepine-induced MPE in Europeans (p = 1.47 × 10−10,
odds ratio [OR] [95% conﬁdence interval (CI)] 5.5
[3.0–10]). Conditioning on HLA-A*31:01 did not reveal
additional variants within the human leukocyte antigen
(HLA) region that were independently contributing to
carbamazepine-induced MPE. No genome-wide signiﬁcant
signals for lamotrigine-induced MPE were observed in
Europeans. This analysis was powered to detect an eﬀect
size >6.
For phenytoin-induced MPE, we identiﬁed a signiﬁcant as-
sociation with rs78239784, an intronic variant of the com-
plement factor H–related 4 gene (CFHR4). The risk allele, G,
had a minor allele frequency of 12% in our European
phenytoin-inducedMPE cases compared to 1.5% in European
phenytoin-tolerant controls (p = 2.94 × 10−10, OR [95% CI]
8.8 [4.0–19]; ﬁgure 2). Conditioning on rs78239784 did not
reveal additional variants in this locus that were independently
contributing to phenytoin-induced MPE. Using 1000
Genomes Phase III European population data, rs78239784
was found to be in complete linkage disequilibrium with
rs35274867 (r2 = 1 and D’ = 1), a missense variant coding for
an asparagine to tyrosine substitution at amino acid 1,050 of
the complement factor H (CFH) gene. The missense variant
was not present in our association results, as it was ﬁltered
during quality control because the imputation score was
<0.95. The imputation accuracy of the top variant rs78239784
was conﬁrmed in our cohort via Sanger sequencing and
TaqMan approaches. Of 100 samples tested, a 100% con-
cordance rate was found between imputed and resequenced
genotypes. Within the Han Chinese subgroup, no signiﬁcant
associations were found between autosomal SNPs or HLA
alleles and AED-speciﬁc MPE. Summary results for known
risk loci in our dataset were scrutinized and are presented in
table 2. None of these loci was even nominally signiﬁcant (p >
0.05) in the Han Chinese subgroup.
In order to test hypothesis (4), that transethnic genetic
markers predispose to AED-speciﬁc MPE, we meta-analyzed
p values from association results for carbamazepine, lamo-
trigine, and phenytoin individually, across European and Han
Chinese ancestral subgroups. There were no shared genome-
wide signiﬁcant markers among our meta-analyses of AED-
speciﬁc MPE (ﬁgure 1, B–D).
Replication of CFHR4 signal
To replicate the association with phenytoin-induced MPE in
an independent cohort, the variant rs78239784 was geno-
typed in self-reported European-descent cases and controls
recruited through centers in Liverpool (United Kingdom),
Sao Paolo (Brazil), and across Canada (CPNDS). Two het-
erozygous carriers were identiﬁed among 13 phenytoin-
induced MPE cases while only a single carrier was observed
among 88 phenytoin-tolerant controls yielding a 2-tailed
Fisher exact p value of 0.044. Pooling all cases and controls
together, we report an overall p value of 4.5 × 10−11 (with
a combined OR [95% CI] 7 [3.2–16]) for the association
between rs78239784 and phenytoin-induced MPE in
Europeans (table 3).
Discussion
We detected a strong association between variants in the
complement factor H regulatory pathway and phenytoin-
induced MPE in a European-descent patient population. The
presence of the associated genotype increases risk for MPE 6-
fold. Our results indicate that risk variants for MPE tend to be
drug-speciﬁc and population-speciﬁc.
These results point to the regulators of complement activa-
tion gene cluster as a genetic locus contributing to the onset of
hypersensitivity to phenytoin. The most signiﬁcant variant in
our European subgroup analysis, rs78239784 (c.59-
2448T>G), tags the missense variant rs35274867 (p.
N1050Y) in CFH, suggesting aberrant complement activation
as a potential causal mechanism in a subset of phenytoin-
sensitive individuals. According to data from the Exome Ag-
gregation Consortium, CFH N1050Y has an allele frequency
of approximately 2% in Europeans, 3% in African sub-
populations, less than 1% in South Asians, and is almost in-
variant in East Asians.17 Given the absence of this allele in East
Asian populations, the lack of an association between theCFH
locus and MPE in our Han Chinese cohort is unsurprising.
We propose that population-speciﬁc, independent rare var-
iants of large eﬀect may explain a proportion of MPE cases,
a similar paradigm to the rare variant model demonstrated in
Crohn disease and ulcerative colitis.18 CFH N1050Y has
previously been associated with type 2 diabetes–associated
end-stage kidney disease in an African American cohort.19
Defects in CFH-related proteins are also associated with
overactivation of the complement immune system and can
lead to atypical hemolytic-uremic syndrome, C3 glomerul-
opathy, basal laminar drusen, immunoglobulin A nephropa-
thies, and systemic lupus erythematosus.20 Further, genetic
variants in CFHR4 and CFH are associated with risk for age-
related macular degeneration.21 We did not detect these
symptoms among N1050Y carriers. While it is unclear
whether phenytoin directly interacts with circulating CFH-
related proteins, it does not speciﬁcally increase serum com-
plement levels.22 Our ﬁndings oﬀer an expanded insight into
the role of the complement alternative pathway in hyper-
sensitivity to AEDs.
Phenytoin is still used as a ﬁrst-line treatment for epilepsy in
many settings and is listed on the WHO list of essential
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medicines.23 Epidemiologic data on prescriptions of AEDs for
epilepsy in the United Kingdom show that, in 2008, phenyt-
oin accounted for 18% of all treated person-years in epilepsy
and was most frequently used in the elderly.24 Therefore,
a clinically useful prognostic test for phenytoin-induced cu-
taneous ADRs in European-ancestral individuals would be
welcome. The sensitivity of theCFHR4 variant as a prognostic
marker is 16% and the speciﬁcity is 97%, which corresponds to
Figure 1Meta-analysis results across European and Han Chinese cohorts
Manhattan (a) and quantile–quantile
(b) plots for the meta-analyses of
maculopapular exanthema vs tolerant
controls, for (A) any antiepileptic drug
(genomic inflation factor [λ] = 1.01), (B)
carbamazepine (λ = 1.01), (C) lamo-
trigine (λ = 0.99), and (D) phenytoin (λ =
0.98).
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a positive likelihood ratio of 5.93 (95% CI 2.8–12.6) and
a negative likelihood ratio of 0.86 (95% CI 0.8–0.9). As-
suming the pretest probability of the ADR is 5%, a positive
test for this marker increases the probability of MPE to
phenytoin sixfold to 30%, while a negative test reduces the
probability marginally to 4.3%. There are an estimated 6
million people with epilepsy in Europe, which means ap-
proximately 90,000 people are at-risk carriers of this muta-
tion.25 We estimate that 208 (95% CI 103–431) patients of
European ancestry would need to be screened to prevent one
case, based on a previously reported formula,26 which corre-
sponds to an absolute risk reduction of 0.005 (95% CI
0.002–0.009). As a comparison, it is estimated that 442 Han
Chinese patients would be needed to screened forHLA-B*15:
02 in order to prevent a single carbamazepine-induced SJS/
TEN case. We would suggest that the clinical utility and cost-
eﬀectiveness of implementing preemptive screening be eval-
uated through a prospective study.
We did not replicate the association between CYP2C9*3
(rs1057910) and MPE in our cohort, irrespective of ethnicity
or AED. This is not surprising given that the original associ-
ation with phenytoin in Han Chinese was largely driven by
SJS/TEN cases, which were excluded from this analysis. We
did, however, detect a nonsigniﬁcant enrichment of
CYP2C9*3 (p = 0.08) among the European phenytoin-
Figure 2 Intronic CFHR4 variants are associated with phenytoin-induced maculopapular exanthema (MPE) in Europeans
(A) Manhattan and (B) quantile–quantile plot of phenytoin-induced MPE in the European subgroup (λ = 1.01). The LocusZoom plot (C) highlights the most
significant single nucleotide polymorphism (SNP), rs78239784 (purple dot), is an intronic variant in CFHR4.
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induced MPE cases, but the eﬀect size we observe (OR 1.8) is
smaller than previously reported for phenytoin-induced MPE
in Han Chinese (OR 5.5).10 Notably, 2 CYP2C9*3 carriers
among the phenytoin-induced MPE cases were also hetero-
zygous for the CFHR4 variant while only 3 of 560 controls
were jointly heterozygous. The frequency of CYP2C9*3 dif-
fers between controls from European and Han Chinese sub-
groups in our study, which is in accordance with background
population frequency reported in the Exome Aggregation
Consortium (European: 7%, East Asian: 3%). While our
results do not support a signiﬁcant eﬀect of CYP2C9*3 in
MPE, larger cohorts including severe cADR cases may resolve
the extent of the association across populations.
HLA-A*31:01 was the most strongly associated marker with
carbamazepine-induced MPE in Europeans in this study.
Forty-three of the 95 cases studied here were also included in
the discovery publication,8 but the eﬀect of the allele remains
signiﬁcant when we restrict to new cases only (p = 4 × 10−7),
thus providing an additional independent replication of the
initial ﬁnding. We conﬁrm thatHLA-B*15:02 is not associated
with carbamazepine-induced MPE in Han Chinese, and no
novel signals emerged for carbamazepine-induced MPE in
either population. No signiﬁcant predictors of lamotrigine-
induced MPE were observed in either population tested.
HLA-A*24:02 was not signiﬁcantly associated with
lamotrigine-induced MPE in either of the European or Han
Chinese ancestral subgroups; rather this allele was observed
to be more frequent among our lamotrigine-tolerant controls.
Our meta-analyses did not reveal any signiﬁcant transethnic
genetic markers for MPE due to any AED. There were con-
siderably more European-descent patients in this analysis than
any other ethnicity, and we recognize this as a limitation of the
study. Analysis of non-European cohorts is warranted. A
second limitation of our study was the low number of Han
Chinese lamotrigine-related MPE cases, relative to European-
descent cases. Therefore we cannot conclusively rule out
genetic predictors of modest eﬀect size for MPE to lamo-
trigine in Han Chinese or other non-European descent pop-
ulations. We recognize that our replication cohort for
phenytoin is small and comprises self-reported ancestral
Europeans. Since we did not have full genotype array data for
these individuals, we relied on Fisher exact test for calculating
signiﬁcance rather than logistic regression with correction for
principal components. Additional studies of larger sample size
are required to further characterize the association, improve
the estimation of the risk eﬀect size, and determine the
prognostic ability and economics of screening for this marker.
Finally, as this study was not powered to investigate MPE
attributed to oxcarbazepine due to low sample size, further
investigation is warranted.
We have identiﬁed a genetic predictor for a common adverse
reaction to phenytoin in European-descent patients, adding
a new pharmacogenetic marker for potential use in the
treatment of epilepsy. This ﬁnding adds to the list of geneticTa
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predictors of hypersensitivity to anticonvulsant therapy and
opens up a new avenue for understanding the biology un-
derlying cutaneous adverse reactions. This ﬁnding can ad-
vance genetic testing in the clinic as it expands the array of
genetic tests available to aid clinicians in reducing overall rates
of discontinuation due to adverse events and improving pa-
tient safety.
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